Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 13/20 | 0.85 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.74 |
| ▸ | PRKACA | P17612 | 3/20 | 0.74 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.74 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.74 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.74 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.74 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.74 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.74 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.74 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.74 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.74 |
| ▸ | PRKX | P51817 | 1/20 | 0.64 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.64 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.64 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.48 |
| ▸ | PRKACG | P22612 | 2/20 | 0.42 |
| ▸ | PRKACB | P22694 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2333115 | 1.00 | ROCK1 (0.85) | ROCK1ROCK2PRKACAPRKCDPRKG1 | |
| SCHEMBL1204582 | 1.00 | ROCK1 (0.85) | ROCK1ROCK2PRKACAPRKCDPRKG1 | |
| SCHEMBL3217279 | 0.95 | ROCK1 (0.82) | ROCK1ROCK2PRKACAPRKCDPRKG1 | |
| SCHEMBL3217268 | 0.95 | ROCK1 (0.82) | ROCK1ROCK2PRKACAPRKCDPRKG1 | |
| SCHEMBL8195235 | 0.95 | ROCK1 (0.82) | ROCK1ROCK2PRKACAPRKCDPRKG1 | |
| SCHEMBL3217262 | 0.95 | ROCK1 (0.82) | ROCK1ROCK2PRKACAPRKCDPRKG1 | |
| SCHEMBL3211552 | 0.92 | ROCK1 (1.00) | ROCK1ROCK2PRKACAPRKCDPRKG1 | |
| SCHEMBL12879288 | 0.92 | ROCK1 (1.00) | ROCK1ROCK2PRKACAPRKCDPRKG1 | |
| SCHEMBL3202747 | 0.92 | ROCK1 (1.00) | ROCK1ROCK2PRKACAPRKCDPRKG1 | |
| SCHEMBL1204565 | 0.86 | ROCK1 (0.86) | ROCK1ROCK2PRKACAPRKCDPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796458-B2 | Cyclohexylamine isoquinolone derivatives | SANOFI (FR) | 2014-08-05 | — | — | US | disclosed |
| US-8609691-B2 | Cyclohexylamin isoquinolone derivatives | SANOFI (FR) | 2013-12-17 | — | — | US | disclosed |
| US-20110251226-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| EP-1912949-B1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI SA (FR) | 2011-08-24 | — | — | EP | disclosed |
| EP-1912949-B1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI SA (FR) | 2011-08-24 | — | — | EP | disclosed |
| US-7893088-B2 | 6-substituted isoquinoline derivatives | N.V. ORGANON (NL) | 2011-02-22 | — | — | US | disclosed |
| EP-2054389-B1 | 6-SUBSTITUTED ISOQUINOLINE DERIVATIVES AS ROCK-1 INHIBITORS | ORGANON NV (NL) | 2010-04-07 | — | — | EP | disclosed |
| US-20080242699-A1 | Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one | SANOFI-AVENTIS (FR) | 2008-10-02 | — | — | US | disclosed |
| EP-1912949-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | Sanofi-Aventis (FR) | 2008-04-23 | — | — | EP | disclosed |
| US-20080045566-A1 | 6-SUBSTITUTED ISOQUINOLINE DERIVATIVES | N.V. ORGANON (NL) | 2008-02-21 | — | — | US | disclosed |
| WO-2007012422-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007012422-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242699-A1 | Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one | MYLK, MYLK2, ROCK1 | ROCK1 3/4885ROCK2 5/4885PRKACA 646/4885 |
| US-20080045566-A1 | 6-SUBSTITUTED ISOQUINOLINE DERIVATIVES | ROCK1, ROCK2, RHOA | ROCK1 1/4885ROCK2 2/4885PRKACA 2658/4885 |
| US-20110251226-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES | MYLK2, MYLK, MYLK3 | ROCK1 7/4885ROCK2 10/4885PRKACA 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.